Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.62 USD

486.62
740,884

+1.86 (0.38%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Steer Clear of Express Scripts for Now

Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.

    Cardinal Health (CAH), CD&R to Jointly Invest in naviHealth

    Cardinal Health (CAH) intends to boost its acute-care program platform by jointly investing in the earlier acquired naviHealth along with Clayton, Dubilier & Rice.

      SYK or SRDX: Which is a Better Medical Product Stock?

      Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.

        3 Medical Instrument Stocks to Gain on Solid Market Prospects

        Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.

          Here's Why You Should Buy Varian Medical (VAR) Stock Now

          Varian Medical's (VAR) solid product portfolio and strong global foothold make it a lucrative pick.

            Medidata Solutions (MDSO) Rallies 10.4% on Solid Q1 Earnings

            Medidata Solutions (MDSO) reports strong Q1 earnings and solid growth across segments.

              CVS Health's PBM Selling Season Remains Solid, Retail Grows

              CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.

                Corindus Vascular Robotics (CVRS) Soars: Stock Adds 14.2% in Session

                Corindus Vascular Robotics (CVRS) saw a big move last session, as its shares jumped more than 14% on the day, amid huge volumes.

                  Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates

                  Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.

                    Bio-Rad Banks on Solid Global Scenario, Competition Rife

                    Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.

                      Why You Should Add IDEXX (IDXX) Stock to Your Portfolio?

                      IDEXX's (IDXX) stellar performance is primarily driven by robust sales at the CAG (Companion Animal Group) business.

                        Here's Why You Should Invest in Genomic Health (GHDX) Now

                        Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.

                          ABMD or VAR: Which is a Better Medical Instrument Stock?

                          It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.

                            ResMed Reports Positive Results for Bilevel PAP Device Study

                            Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.

                              Varian to Demonstrate Brachytherapy Solutions Portfolio

                              Varian (VAR) will demonstrate four brachytherapy solutions in the American Brachytherapy Society Annual Meeting in San Francisco.

                                STERIS (STE) Benefits From Core Business Expansion, Buyouts

                                STERIS' (STE) strong organic growth across specialty services, life sciences and applied sterilization segments raises optimism on the stock.

                                  Becton, Dickinson Ties Up With Helmer Scientific to Boost MMS

                                  Becton, Dickinson (BDX) aims to boost its MMS segment through the promotion of its Pyxis ES refrigerator.

                                    Here's Why You Should Sell Cardinal Health (CAH) Stock Now

                                    Cardinal Health (CAH) faces sluggishness in the exam-gloves unit lately. Further, cutthroat competition in the niche space is a headwind.

                                      Here's Why You Should Buy Abiomed (ABMD) Stock Right Now

                                      Abiomed's (ABMD) solid Impella product line and the inclusion in the S&P 500 connect make it a lucrative pick.

                                        Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up

                                        Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.

                                          Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe

                                          The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.

                                            NuVasive's (NUVA) Global Prospects Solid, Competition Rife

                                            NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.

                                              Here's Why You Should Invest in Stryker (SYK) Stock Now

                                              Stryker's (SYK) focus on inorganic expansion and stellar Mako performance make the stock an attractive buy.

                                                Boston Scientific Grows on New Products Amid Recall Issues

                                                Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

                                                  Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

                                                  Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.